Efficacy of N-acetylcysteine Treatment in Methimazole-induced Myopathy and Toxic Hepatitis

Kasap, Elmas; BURAN, TAHİR; İNCE, Burcu ALMACAN; ŞAHİN, Mustafa; ayhan, semin

doi:10.5336/caserep.2020-77783

Efficacy of N-acetylcysteine Treatment in Methimazole-induced Myopathy and Toxic Hepatitis

Tahir BURAN, (Girilmemişş)

Mustafa ŞAHİN, (Girilmemişş)

Elmas KASAP, (Girilmemişş)

Semin AYHAN, (Girilmemişş)

Burcu ALMACAN İNCE (Girilmemişş)

Türkiye Klinikleri Journal of Case Reports

36 1

Yıl: 2020 Cilt: 28 Sayı: 4 Sayfa Aralığı: 266 - 271 Metin Dili: İngilizce DOI: 10.5336/caserep.2020-77783 İndeks Tarihi: 27-06-2021

Efficacy of N-acetylcysteine Treatment in Methimazole-induced Myopathy and Toxic Hepatitis

Öz:

Today, antithyroid drugs are widely used in the treatment of hyperthyroidism. Elevated creatine kinase and liver injury (hepatitis) caused by methimazole are some of rare side effects. Elevation of creatine kinase (CK) should be monitored due to the risk of rhabdomyolysis development. Also, drug-induced liver injury can be seen. In this article, we report a patient who received methimazole 2 monthsago for hyperthyroidism, but then began to have complaints like muscle pain, jaundice (icterus) in the eyes along with itching and dark urine,and found out to have elevated CK as well as liver enzymes induced by liver injury, thus showed rapid recovery upon N-acetylcysteine treatment.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık

1. Burch HB, Bahn RS. Graves ophthalmopathy. In: Larrooy Jameson JL, De Groot LJ, eds. Endocrinology Adult and Pediatric. 7th ed. Philadelphia; Elsevier-Saunders: 2015. p.1456-7.
2. Arıcı S. [Toxic hepatitis]. Pamukkale Medical Journal. 2008;1(2):113-9.
3. Karsen H, Çalışır C, Duygu F, Karaağaç L, Tavşan Ö. [Acute hepatitis due to use of herbal tea to lose weight: a case report]. Van Med J. 2011;18(2):110-2.
4. Bonkovsky HL, Jones DP, LaBrecque DR, Shedlofsky S. Drug-induced liver injury. In: Boyer TD, Wright TL, Manns MP, eds. Zakim and Boyer's Hepatology, a Textbook of Liver Disease. Vol. 1. 5th ed. Edinburgh: Elsevier Saunders; 2006. p.503-50. [Crossref]
5. Hu J, Zhang Q, Ren X, Sun Z, Quan Q. Efficacy and safety of acetylcysteine in "non-acetaminophen" acute liver failure: a meta-analysis of prospective clinical trials. Clin Res Hepatol Gastroenterol. 2015;39(5):594- 9. [Crossref] [PubMed]
6. Lane RJ, Mastaglia FL. Drug-induced myopatihes in man. Lancet. 1978;2(8089):562-6. [Crossref] [PubMed]
7. Sieb JP, Gillessen T. Iatrogenic and toxic myopathies. Muscle Nerve. 2003;27(2):142-56. [Crossref] [PubMed]
8. Suzuki S, Ichikawa K, Nagai M, Mikoshiba M, Mori J, Kaneko A, et al. Elevation of serum creatine kinase during treatment with antithyroid drugs in patients with hyperthyroidism due to graves disease. A novel side effect of antithyroid drugs. Arch Intern Med. 1997;157(6):693-6. [Crossref] [PubMed]
9. Ito T, Katahira M, Hanakita M, Suzuki. A case of elevation of serum creatine kinase with antithyroid medications for Graves' disease. J Endocrinol Metab. 2012;2(6):244-7. [Crossref]
10. Mizuno H, Sugiyama Y, Nishi Y, Ueda N, Ohro Y, Togari H. Elevation of serum creatine kinase in response to medical treatment of Graves' disease in children. Acta Paediatr. 2006;95(2):243-5. [Crossref] [PubMed]
11. Kim H, Kim J, Huh R, Cho SY, Jin DK. Elevation of serum creatine kinase during methimazole treatment of graves disease in a 13-year-old girl and a literature review of similar cases. Ann Pediatr Endocrinol Metab. 2015;20(2):106-9. [Crossref] [PubMed] [PMC]
12. Hillman L, Gottfried M, Whitsett M, Rakela J, Schilsky M, Lee WM, et al. Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury. Am J Gastroenterol. 2016;111(7):958- 65. [Crossref] [PubMed] [PMC]
13. Arab DM, Malatjalian DA, Rittmaster RS. Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole. J Clin Endocrinol Metab. 1995;80(4):1083-5. [Crossref] [PubMed]
14. Blom H, Stolk J, Schreuder HB, von Blomberg-van der Flier M. A case of carbimazole-induced intrahepatic cholestasis. An immune-mediated reaction? Arch Intern Med. 1985;145(8):1513-5. [Crossref] [PubMed]
15. Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab. 2010;95(7):3260-7. [Crossref] [PubMed]
16. Gallelli L, Staltari O, Palleria C, De Sarro G, Ferraro M. Hepatotoxicity induced by methimazole in a previously healthy patient. Curr Drug Saf. 2009;4(3):204-6. [Crossref] [PubMed]
17. Woeber KA. Methimazole-induced hepatotoxicity. Endocr Pract. 2002;8(3):222-4. [Crossref] [PubMed]
18. Noureddin N, Kaplowitz N. Overview of mechanisms of drug-induced liver injury (DILI) and key challenges in DILI research. In: Chen M, Will Y, eds. Drug-Induced Liver Toxicity. Methods in Pharmacology and Toxicology series. New York, USA: Humana Press; 2018. p.3-18. [Crossref]
19. Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J. 2006;8(1):E48-54. [Crossref] [PubMed] [PMC]
20. Shen C, Zhao CY, Liu F, Wang YD, Yu J. Acute-on-chronic liver failure due to thiamazole in a patient with hyperthyroidism and trilogy of fallot: case report. BMC Gastroenterol. 2010;10:93. [Crossref] [PubMed] [PMC]
21. Nabi T, Nabi S, Rafiq N, Shah A. Role of nacetylcysteine treatment in non-acetaminophen-induced acute liver failure: a prospective study. Saudi J Gastroenterol. 2017;23(3):169-175. [PubMed]
22. Hung Y, Yu WK, Chow E. Delayed cholestatic hepatitis due to methimazole. Hong Kong Med J. 1999;5:200-1.
23. Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, et al. Intravenous nacetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3): 856-64, 864.e1. [Crossref] [PubMed] [PMC]
24. Johnson K, McEvoy CE, Naqvi S, Wendt C, Reilkoff RA, Kunisaki KM, et al. High-dose oral n-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis. 2016;11:799- 807. [Crossref] [PubMed] [PMC]
25. Smilkstein MJ, Bronstein AC, Linden C, Augenstein WL, Kulig KW, Rumack BH. Acetaminophen overdose: a 48-hour intravenous n-acetylcysteine treatment protocol. Ann Emerg Med. 1991;20(10):1058-63. [Crossref] [PubMed]

APA	BURAN T, ŞAHİN M, Kasap E, ayhan s, İNCE B (2020). Efficacy of N-acetylcysteine Treatment in Methimazole-induced Myopathy and Toxic Hepatitis. , 266 - 271. 10.5336/caserep.2020-77783
Chicago	BURAN TAHİR,ŞAHİN Mustafa,Kasap Elmas,ayhan semin,İNCE Burcu ALMACAN Efficacy of N-acetylcysteine Treatment in Methimazole-induced Myopathy and Toxic Hepatitis. (2020): 266 - 271. 10.5336/caserep.2020-77783
MLA	BURAN TAHİR,ŞAHİN Mustafa,Kasap Elmas,ayhan semin,İNCE Burcu ALMACAN Efficacy of N-acetylcysteine Treatment in Methimazole-induced Myopathy and Toxic Hepatitis. , 2020, ss.266 - 271. 10.5336/caserep.2020-77783
AMA	BURAN T,ŞAHİN M,Kasap E,ayhan s,İNCE B Efficacy of N-acetylcysteine Treatment in Methimazole-induced Myopathy and Toxic Hepatitis. . 2020; 266 - 271. 10.5336/caserep.2020-77783
Vancouver	BURAN T,ŞAHİN M,Kasap E,ayhan s,İNCE B Efficacy of N-acetylcysteine Treatment in Methimazole-induced Myopathy and Toxic Hepatitis. . 2020; 266 - 271. 10.5336/caserep.2020-77783
IEEE	BURAN T,ŞAHİN M,Kasap E,ayhan s,İNCE B "Efficacy of N-acetylcysteine Treatment in Methimazole-induced Myopathy and Toxic Hepatitis." , ss.266 - 271, 2020. 10.5336/caserep.2020-77783
ISNAD	BURAN, TAHİR vd. "Efficacy of N-acetylcysteine Treatment in Methimazole-induced Myopathy and Toxic Hepatitis". (2020), 266-271. https://doi.org/10.5336/caserep.2020-77783

APA	BURAN T, ŞAHİN M, Kasap E, ayhan s, İNCE B (2020). Efficacy of N-acetylcysteine Treatment in Methimazole-induced Myopathy and Toxic Hepatitis. Türkiye Klinikleri Journal of Case Reports, 28(4), 266 - 271. 10.5336/caserep.2020-77783
Chicago	BURAN TAHİR,ŞAHİN Mustafa,Kasap Elmas,ayhan semin,İNCE Burcu ALMACAN Efficacy of N-acetylcysteine Treatment in Methimazole-induced Myopathy and Toxic Hepatitis. Türkiye Klinikleri Journal of Case Reports 28, no.4 (2020): 266 - 271. 10.5336/caserep.2020-77783
MLA	BURAN TAHİR,ŞAHİN Mustafa,Kasap Elmas,ayhan semin,İNCE Burcu ALMACAN Efficacy of N-acetylcysteine Treatment in Methimazole-induced Myopathy and Toxic Hepatitis. Türkiye Klinikleri Journal of Case Reports, vol.28, no.4, 2020, ss.266 - 271. 10.5336/caserep.2020-77783
AMA	BURAN T,ŞAHİN M,Kasap E,ayhan s,İNCE B Efficacy of N-acetylcysteine Treatment in Methimazole-induced Myopathy and Toxic Hepatitis. Türkiye Klinikleri Journal of Case Reports. 2020; 28(4): 266 - 271. 10.5336/caserep.2020-77783
Vancouver	BURAN T,ŞAHİN M,Kasap E,ayhan s,İNCE B Efficacy of N-acetylcysteine Treatment in Methimazole-induced Myopathy and Toxic Hepatitis. Türkiye Klinikleri Journal of Case Reports. 2020; 28(4): 266 - 271. 10.5336/caserep.2020-77783
IEEE	BURAN T,ŞAHİN M,Kasap E,ayhan s,İNCE B "Efficacy of N-acetylcysteine Treatment in Methimazole-induced Myopathy and Toxic Hepatitis." Türkiye Klinikleri Journal of Case Reports, 28, ss.266 - 271, 2020. 10.5336/caserep.2020-77783
ISNAD	BURAN, TAHİR vd. "Efficacy of N-acetylcysteine Treatment in Methimazole-induced Myopathy and Toxic Hepatitis". Türkiye Klinikleri Journal of Case Reports 28/4 (2020), 266-271. https://doi.org/10.5336/caserep.2020-77783